# China NMPA Drug Inspection - Baoji Kexing Pharmaceutical Co., Ltd. - Typha pollen

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/baoji-kexing-pharmaceutical-co-ltd/464e2e69-c873-44e9-ad67-d923cd8a40aa/
Source feed: China

> China NMPA drug inspection for Baoji Kexing Pharmaceutical Co., Ltd. published June 08, 2018. Drug: Typha pollen. The Gansu Provincial Food and Drug Administration issued a Drug Quality Announcement on June 7, 2018, detailing provinci

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Gansu Provincial Food and Drug Administration Drug Quality Announcement
- Company Name: Baoji Kexing Pharmaceutical Co., Ltd.
- Publication Date: 2018-06-08
- Drug Name: Typha pollen
- Inspection Finding: It does not meet the requirements for [characteristics] and [identification] (microscopic examination).
- Action Taken: Relevant food and drug regulatory authorities have taken control measures such as sealing and seizing products, requiring the company to suspend the sale and use of its products and to rectify the situation. The provincial bureau has ordered an investigation into the illegal activities and will release the results of the investigation within three months.
- Summary: The Gansu Provincial Food and Drug Administration issued a Drug Quality Announcement on June 7, 2018, detailing provincial supervision and sampling inspections of traditional Chinese medicine (TCM) decoction pieces. The inspections specifically targeted products known for previous non-compliance, adulteration, counterfeiting, or issues like dyeing, weight-increasing, and sulfur fumigation.A total of 30 batches from various manufacturers and suppliers across the province were found to be non-compliant. Key violations included failures in "Appearance," "Identification," "Characteristics," "Total Ash," and "Content Determination," as well as "Sulfur dioxide residue" for certain items, indicating quality defects and potential adulteration. These findings directly contravened standards set forth in the "Chinese Pharmacopoeia 2015 Edition, Part I" and "2010 Edition, Part I."In response, the relevant food and drug administration departments initiated control measures, including the sealing and seizing of non-compliant products, and mandated that enterprises suspend sales, cease use, and rectify all identified issues. Furthermore, municipal authorities were instructed to investigate and prosecute illegal production and sale of substandard drugs under the "Drug Administration Law of the People's Republic of China." They are required to publicly disclose the enforcement outcomes for involved entities within three months, reinforcing the commitment to public medication safety.

Company: https://www.globalkeysolutions.net/companies/baoji-kexing-pharmaceutical-co-ltd/44e3a9b3-9eec-43ec-b3ed-7865eae98af9/